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'Common. costly and deadly'. This in a nutshell describes the condition 
we traditionally refer to as Cardiac Failure. Indeed 'Circulatory failure' 
\\iould be a more appropriate teml as it is a combination of factors that 
involve not only the heart but other organs such as the kidney and brain 
as well as tl1e peripheral circulation. The management of this condition 
includes pharmacological and surgical approaches as well as a number of 
devices that have been developed in recent years in order to improve the 
significant morbidity as well as mortality associated with it. 
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ami! or ventricular fibrillation without any 
prior evidence of clinical deterioration. It 
is therefore imperative to avoid low levels 
of serum Potassium as well as Magnesium, 
both of which are important for myocardial 
cellular electrical stability. Nitrates and 
direct acting vasodilators can be useful in 
modifYing preload and afterload and after 
a long period of controversy Digitalis has 
again found a place in the therapeutic 
armamentarium - albeit in a very limited 
role. All these drugs can improve symptoms 
but do nothing for the overall mortality. 
Drugs that have an impact on both 
morbidity and mortality include ACE 
inhibitors and Beta Blockers, both of 
which should be prescribed (unless 
contraindicated) as first line on a 'some 
better than none' basis. ACE inhibitors 
are indicated in all classes of heart failure 
(New York Heart Association I to IV) 
whereas Beta Blockers are contraindicated 
in NYHA class IV patients. If ACE 
inhibitors are not tolerated because of 
untoward side effects then Angiotensin-
II Receptor Blockers can be used. 
Spironolactone is another drug that 
improves mortality though it is used as a 
third line drug and can be limited by side 
effects which appear to be less with its 
successor Epelrenone. For a number of 
years the use of Amiodarone was suggested 
as being of potential benefit in reducing 
mortality due to its antiarrhythmic 
properties. It is now established that litis 
drug offers no benefit whatsoever in 
patients with cardiac failure. 
Despite all the measures hitherto 
mentioned a considerable number of 
patients do not respond adequately 
or have such a degree of left 
ventricular impairment that the use 
of certain devices is indicated. Up 
to half the patients with congestive 
heart failure have intra ventricular 
conduction defects which can result 
in 'Ventricular Dysynchrony'. This 
label describcs thc situation whcn thc 
septal portion of the left ventricle 
contracts before the lateral wall (of 
the left ventricle). These normally 
contract simultaneously (in 
synchrony) ej ecting blood out of the 
ventricle into the Aorta so the lack 
of synchrony results in a portion of 
blood inside the left ventricle being 
pushed from one side of the ventricle 
to the other instead of through the 
Aortic valve into the circulation. In 
addition, left ventricular dysynchrony 
causes inefficien t closure of the Mitral 
Valve which results in functional 
Mitral Regurgitation, thus further 
elevating the pulmonary pressure . 
It is possible to correct this situation 
by inserting a pacemaker that paces both 
the septum and the lateral wall of the 
left ventricle simultaneously thus 
'synchronising' the contraction and 
improving Mitral valve closure with a 
resultant improvement in cardiac output 
and pulmonary pressure . Keeping in 
mind that these patients are prone to 
ventricular tachycardia and/or 
ventricular fibrillation the pacing 
function of these devices is 
supplemented with an anti-tachycardia 
and defibrillation capability that has 
significantly improved the patient's 
symptoms as well as improving 
morbidity and mortality. 
Cardiac surgical techniques are 
available for patients with relenting 
cardiac failure , the most successful of 
which has been cardiac transplantation. 
The major problem is a lack of suitable 
donors with the majority of patients 
dying while waiting for a suitable heart. 
In this context a number of left 
ventricular assist devices (LVADs) have 
been developed which can help the 
individual for a period of time thus 
'bridging' the time to clinical 
improvement or transplantation. The 
most commonly available device is the 
intr a-aurtic balluun device (IADD) 
which is a balloon counterpulsation 
device inserted percutaneously into the 
descending aorta . Its rapid inflation 
during diastole helps boost the blood 
pressure as well as the coronary 
circulation and the rapid deflation 
during systole helps in offloading the 
left ventricle. 
More recent mechanical devices that 
can generate a cardiac output of up 
to 4.5 litres/minute include the 
'Impella' device (Figure 1) that is a 
miniature turbine inserted across the 
aortic valve into the left ventricle 
ejecting blood into the aorta. 
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Assessment of People with Memory Symptoms 
continued ~om page 8 
The initial assessment of a person 
presenting with a dementia syndrome 
continues with blood investigations 
and imaging to exclude secondary and 
potentially reversible causes. These 
should include a complete blood 
picture, erythrocyte sedimentation rate, 
electrolyte and renal function tests , 
liver function tests, serum calcium, 
thyroid function tests, serum Vitamin 
B 12 and folate levels. A CT scan of 
the brain is indicated to exclude a space 
occupying lesion or to detect features 
of a normal pressure hydrocephalus. A 
SPECT scan is particularly useful to 
see whether decreased tracer uptake is 
diffuse or focal. In vascular dementia, 
it is possible to identify a patchy loss 
of tracer uptake corresponding to the 
ischaemic regions. MRI and functional 
imaging techniques e.g. functional 
SPECT are becoming increasingly used 
in specialised centres . 
Although there is no definite cure for 
dementia, the availahility of specific 
anti-dementia drugs such as the 
cholinesterase inhibitors rivastigmine 
and me man tine can lead to 
improvement in cognitive function and 
symptomatic improvement, thus 
delaying the need for institutionalization. 
Dementia care has become a specialized 
subject, necessitating the collaboration 
of the primary care team and specialists 
in geriatric medicine, neurology and 
psychiatry. Education, training and 
support of persons with dementia and 
caregivers, but also of healthcare staff 
constitute a major area in need of 
attention if we are to face the challenges 
that lie ahead. @ 
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